Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP3507 in Recurrent Grade 2 or 3 Meningioma
NCT07533942Phase 2Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jul 2026
- Primary completion
- Oct 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ONC206 in meningioma, sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Overall Response Rate up to 36 months. Started Jul 2026; status: recruiting.
02
Drugs
ONC206
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT07533942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533942.